lobaplatin + nab-paclitaxel + tislelizumab

This is a combination therapy consisting of three distinct agents:\n\n**Tislelizumab** is a monoclonal antibody that targets PD-1 (programmed death receptor 1). It blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2), preventing cancer cells from evading immune detection. Unlike some other PD-1 inhibitors, tislelizumab is specifically engineered to minimize binding to FcγR on macrophages, which reduces antibody-dependent phagocytosis and potentially improves efficacy. By blocking the PD-1/PD-L1 pathway, tislelizumab restores T-cell function through enhanced cytokine production, resulting in immune-mediated antitumor activity.\n\n**Lobaplatin** is a platinum-based chemotherapeutic agent.\n\n**Nab-paclitaxel** (albumin-bound paclitaxel) is a taxane chemotherapy that inhibits cell division by stabilizing microtubules.\n\nThis triple combination likely aims to leverage both immunotherapy and chemotherapy mechanisms for enhanced anticancer effects.